Compared with other agonists, M8 holds a stronger ability to stimulate antiviral immunity (Chiang et al., 2015) and blocks viral infections in vitro and in vivo by activating a broader and intense innate immune response (Beljanski et al., 2015). Here, PRNT is linked to viral infectious disease.